Home › Compare › YMTX vs ADC

YMTX vs ADC: Dividend Comparison 2026

YMTX yields 105.82% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YMTX wins by $4.75M in total portfolio value
10 years
YMTX
YMTX
● Live price
105.82%
Share price
$1.89
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.93M
Annual income
$1,723,843.10
Full YMTX calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — YMTX vs ADC

📍 YMTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYMTXADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YMTX + ADC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
YMTX pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMTX
Annual income on $10K today (after 15% tax)
$8,994.71/yr
After 10yr DRIP, annual income (after tax)
$1,465,266.64/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, YMTX beats the other by $1,397,566.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMTX + ADC for your $10,000?

YMTX: 50%ADC: 50%
100% ADC50/50100% YMTX
Portfolio after 10yr
$2.55M
Annual income
$901,745.17/yr
Blended yield
35.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

YMTX
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-21.9
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMTX buys
0
ADC buys
0
No recent congressional trades found for YMTX or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYMTXADC
Forward yield105.82% ✓4.11%
Annual dividend / share$2.00$3.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4% ✓
Portfolio after 10y$4.93M$176.9K ✓
Annual income after 10y$1,723,843.10 ✓$79,647.25
Total dividends collected$4.43M$154.7K ✓
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: YMTX vs ADC ($10,000, DRIP)

YearYMTX PortfolioYMTX Income/yrADC PortfolioADC Income/yrGap
1← crossover$21,282$10,582.01$10,987$577.21+$10.3K → YMTX
2$43,819$21,047.33$12,293$855.34+$31.5K → YMTX
3$87,387$40,500.83$14,088$1,290.70+$73.3K → YMTX
4$168,990$75,485.74$16,660$1,994.91+$152.3K → YMTX
5$317,245$136,425.12$20,525$3,181.85+$296.7K → YMTX
6$578,807$239,355.52$26,654$5,286.90+$552.2K → YMTX
7$1,027,455$408,130.85$37,006$9,259.47+$990.4K → YMTX
8$1,776,463$677,086.81$55,862$17,338.74+$1.72M → YMTX
9$2,994,908$1,094,092.83$93,452$35,300.32+$2.90M → YMTX
10$4,928,395$1,723,843.10$176,931$79,647.25+$4.75M → YMTX

YMTX vs ADC: Complete Analysis 2026

YMTX — Stock

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Full YMTX Calculator →

ADC — REIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this YMTX vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMTX vs SCHDYMTX vs JEPIYMTX vs OYMTX vs KOYMTX vs MAINYMTX vs NNNYMTX vs EPRTYMTX vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.